Price History
Feb 9, 2026 — May 6, 2026Investment Snapshot
- Trading 4% below Graham Number — thin margin of safety
- Piotroski F-Score 4/9 — moderate financial health
- ROE of 13.4% — below-average profitability
- Dividend yield of 3.3%
Pfizer, Inc. Common Stock (PFE) is a Healthcare company operating in Pharmaceutical Preparations, listed on the NYSE , with a market capitalisation of $150.8 billion . Key value metrics: P/E ratio 12.5, P/B ratio 1.67, Piotroski F-Score 4 out of 9 (moderate financial health) .
Value Score
Key Metrics
Current vs 5-Year Average
Based on 5 years of SEC filingsRevenue & Net Income
Financial Statements
| Metric | FY22 | FY23 | FY24 |
|---|---|---|---|
| Revenue | $X.XB | $X.XB | $X.XB |
| Gross Profit | $X.XB | $X.XB | $X.XB |
| Operating Income | $X.XB | $X.XB | $X.XB |
| Net Income | $X.XB | $X.XB | $X.XB |
| EBITDA | $X.XB | $X.XB | $X.XB |
| Total Assets | $X.XB | $X.XB | $X.XB |
| Total Liabilities | $X.XB | $X.XB | $X.XB |
Pfizer, Inc. Common Stock — Fundamental Analysis Summary
Pfizer, Inc. Common Stock (PFE) is trading 4% below its Graham Number of $27.49, offering a thin margin of safety. The stock carries a reasonable trailing P/E ratio of 12.5x.
On financial health, PFE shows a moderate Piotroski F-Score of 4/9, and modest return on equity of 13.4% (sector average: -20.6%), and manageable leverage with a debt-to-equity ratio of 0.72.
StockPik's composite Value Score for PFE is 72/100 — placing it in undervalued territory. The score is built from ten fundamental signals: P/E, P/B, PEG ratio, P/S ratio, return on equity, gross margin, debt-to-equity, current ratio, dividend yield, and Piotroski F-Score.
PFE shows revenue declining at 2% year-over-year, with earnings declining at 3%.
PFE pays a solid dividend yield of 3.3%.